Company Filing History:
Years Active: 2025
Title: John Beadle - Innovator in Oncolytic Adenovirus Treatment
Introduction
John Beadle, an accomplished inventor based in Abingdon, GB, has made significant contributions to the field of biotechnology. He is particularly known for his innovative work in developing treatment methods involving oncolytic adenoviruses, which hold promise for cancer therapies.
Latest Patents
Beadle holds a patent for his invention titled "Dosing regime and formulations for type B adenoviruses." This patent presents a comprehensive method for treating patients with a replication-capable oncolytic adenovirus of subgroup B. The methodology involves systematically administering multiple doses of a parenteral formulation within a treatment cycle. Notably, the total dose delivered in each instance ranges from 1×10 to 1×10 viral particles, with careful timing for the administration over a duration of 1 to 90 minutes. Additionally, the patent covers formulations of the adenoviruses and potential combination therapies with other therapeutic agents.
Career Highlights
John Beadle is currently associated with Akamis Bio Limited, a company focused on advancing therapeutic solutions in the field of oncology. His expertise and dedication to innovative healthcare solutions have significantly impacted the development of treatments aimed at addressing challenging medical conditions.
Collaborations
In his professional journey, Beadle collaborates closely with Christine Wilkinson Blanc, a fellow innovator within the same field. Their combined efforts at Akamis Bio Limited aim to propel advancements in cancer treatment and the effective use of oncolytic viruses.
Conclusion
John Beadle's innovative approach to formulating adenoviral treatments marks a pivotal advancement in the oncology domain. His dedication and notable patent contributions signal a promising path toward enhancing patient care through groundbreaking therapies. As he continues his work at Akamis Bio Limited, the impact of his inventions is set to shape the future of cancer treatment.